Sanofi and Biovac, a Cape Town, South Africa-based biopharmaceutical business, have announced a local manufacturing agreement to produce inactivated polio vaccines (IPV) in Africa. This partnership aims to enable regional manufacturing of polio...
Sun Pharmaceutical Industries Limited stated that it has signed a non-exclusive patent licensing deal with Takeda Pharmaceutical Company Limited (Takeda) to market vonoprazan tablets 10 mg and 20 mg in India under the brand name "Voltapraz"...
Roche, a swiss based healthcare firm, declared the launch of the first clinically approved, highly sensitivity in-situ hybridisation (ISH) test, the VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay in nations embracing the CE Mark...
Aethlon Medical, Inc., a medical therapeutic company dedicated to creating products to treat cancer and life-threatening infectious illnesses, declared that the Human Research Ethics Committee (HREC) of the Central Adelaide Local Health Network...
Merck reported that the US Food and Drug Administration (FDA) has approved Keytruda, the company's anti-PD-1 medication, in combination with carboplatin and paclitaxel, followed by Keytruda as a single agent, for the treatment of adult patients...
LSL PHARMA GROUP INC., a Canadian based pharmaceutical firm, is pleased to declare the acquisition of Virage Santé, a firm, that specializes in the production and distribution of natural health products (NHPs). LSL Pharma's contract development...
Cipla, a leading global pharmaceutical firm, announced that it will make an additional investment of 3 million euros in Ethris, a company based in Germany that is developing potential treatments for respiratory diseases using its own mRNA...
Aprea Therapeutics, Inc., a biopharmaceutical firm that specializes in precision oncology through synthetic lethality, declared that the first patient has been dosed in the ACESOT-1051 phase 1 study. The study evaluates which is evaluating the...
MGI, an organization focused on building center instruments and advances that drive development in life science, declared partnership with SeqOne, a leading provider of artificial intelligence driven genomic choice support software...
AstraZeneca's Imfinzi (durvalumab) has been approved as a treatment for adult patients with mismatch repair deficient (dMMR) primary, advanced, or recurrent endometrial cancer, in the United States. This can be followed by Imfinzi...
, CDSCO.jpg)
